trial summary · NCT07281924
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
A Phase 1b/2 Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of Melphalan Percutaneous Hepatic Perfusion Therapy (HEPZATO KIT™) With Nivolumab and Relatlimab (Opdualag) in Patients With Metastatic Melanoma and Liver Metastasis
Trial record from the TrialBase DB dataset, status RECRUITING, condition Metastatic Melanoma, sponsored by University of Wisconsin, Madison. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.
Source record: https://clinicaltrials.gov/study/NCT07281924
Facts
| registry id | NCT07281924 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Metastatic Melanoma |
| sponsor | University of Wisconsin, Madison |
| sponsor class | OTHER |
| enrollment | 15 |
| start date | 2026-11 |
| primary completion | 2030-12 |
| completion | 2030-12 |
| results posted | not reported |
Conditions
- Metastatic Melanoma
- Liver Metastases
Interventions
- Nivolumab and Relatlimab
- Melphalan
Countries
- United States
Intervention types: DEVICE, DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.